Vnitr Lek 2005, 51(2):145-147

Heparinem indukovaná trombocytopenie (HIT) - editorial

J. Malý
II. interní klinika Lékařské fakulty UK a FN, Hradec Králové, přednosta prof. MUDr. Jaroslav Malý, CSc.

Received: January 5, 2004; Published: February 1, 2005  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Malý J. Heparinem indukovaná trombocytopenie (HIT) - editorial. Vnitr Lek. 2005;51(2):145-147.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Chong BH. Heparin induced thrombocytopenia. J Thrombos Haemostas 2003; 7(1):1471-1478. Go to original source... Go to PubMed...
    2. Verstraete M, Zoldhelyi P. Novel antithrombotic drugs in development. Drugs 1995; 49: 856-884. Go to original source... Go to PubMed...
    3. Hirsh J, Warkentin TE, Shaughnessy SG et al. Heparin and low molecular weight heparin. Chest 2001; 119: 64S-94S. Go to original source... Go to PubMed...
    4. Bauer KA, Eriksson BI, Lassen MR et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective knee surgery. N Engl J Med 2001; 344: 1305-1310. Go to original source... Go to PubMed...
    5. Bounameaux H, Perneger T. Fondaparinux: a new synthetic pentasaccharide for thrombosis prevention. (Editorial) Lancet 2002; 359: 1710-1715. Go to original source... Go to PubMed...
    6. Eriksson BI, Lassen MR. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: A multicenter, randomized, placebo-controlled, double-blind study. Arch Intern Med 2003; 163: 1337-1342. Go to original source... Go to PubMed...
    7. Eriksson BI, Bauer KA, Lassen MR et al. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after hip-fracture surgery. N Engl J Med 2001; 345: 1298-1304. Go to original source... Go to PubMed...
    8. Eriksson H, Wählender K, Lundström T. et al. Extended secondary prevention with oral direct thrombin inhibitor ximelagatran for 18 months after 6 months of anticoagulation with venous thromboembolism: a randomized, placebo controlled trial. (Abstract) Blood 2002; 100: 81a.
    9. Greinacher A, Völpel H, Jansens U et al. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with the immunologic type of heparin-induced thrombocytopenia a prospective study. Circulation 1999; 99: 73-80. Go to original source... Go to PubMed...
    10. Lewis BE, Wallis DE, Berakowitz SD et al. For the ARG-911 study investigators. Argatroban anticoagulant therapy in patients with heparin induced thrombocytopenia. Circulation 2001; 103: 1038-1043. Go to original source... Go to PubMed...
    11. Francis CW et al. Randomized, double-blind, comparison of ximelagatran, an oral direct thrombin inhibitor, and warfarin to prevent venous thromboembolism after total knee replacement. The 44th Annual Meeting of the American Society of Hermatology, abstract 300. Huisman M. International Society on Thrombosis and Haemostasis XIX Congress 2003; Birmingham, UK: 12-18 July 2002.
    12. Eriksson BI, Berqvist D, Kälebo P et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360: 1441-1447. Go to original source... Go to PubMed...
    13. Turpie AG, Gallus AS, Hoek JA. A synthetic pentasacharide for prevention of deep vein thrombosis after total hip replacement. N Engl J Med 2001, 344: 619-625. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.